SHARE is an easy-to-search, real-time repository of HIV-related systematic reviews. Whether you’re a researcher, community member, healthcare provider or policymaker, SHARE provides a ‘one-stop shop’ for HIV-related information that has been published through a systematic review.

Background: Dolutegravir (DTG) + lamivudine (3TC) has demonstrated efficacy and safety in phase 3 clinical trials; however, most published data are from people with HIV-1 in North America and Europe. Methods: To...

Objective/Background Transmission-dynamic models are commonly used to study infectious disease epidemiology. Calibration involves identifying model parameter values that align model outputs with observed data or other evidence. Inaccurate calibration and...

HIV-related stigma remains a major barrier to testing, treatment, and quality of life, especially for the growing population of older people living with HIV (OPLWH, aged 50+). Such stigma intersects...

BACKGROUND: HIV literature shows that gay, bisexual and men who have sex with other men (GBMSM) experience inequities across social and contextual factors. Given growing inequities, this study used complex...

BACKGROUND: Pre-exposure prophylaxis (PrEP) is a medicine that can reduce HIV transmission. Given the disproportionate impact of HIV on minority communities, health equity is an important consideration in PrEP research....

Background: HIV infection in patients undergoing Total joint arthroplasty (TJA) results in adverse postoperative outcomes. However, there are uncertain data regarding the extent of involvement of HIV in TJA and the...

BACKGROUND: The use of highly active antiretroviral therapy has transformed AIDS into a chronic infectious disease, but issues of chronic inflammation and immune system activation persist. Modulating the gut microbiome...

Objective: Scaling up pre-exposure prophylaxis (PrEP) is critical to combating the AIDS epidemic, especially among PrEP-eligible men who have sex with men (MSM). This study summarizes the global proportion of PrEP-eligible...

Background Kidney dysfunction among adults living with Human Immuno-Deficiency Virus (HIV) increases the risk of drug-related side effects, acute kidney injury, hospitalization, and progression to end-stage kidney disease. In developing...

Background: Measuring progress towards the WHO 2030 target for hepatitis C virus (HCV) elimination among people who inject drugs (PWID)-an incidence of two or fewer infections per 100 person-years-has been challenging...

Background Antiretroviral therapy (ART) and ART adherence are crucial for preventing HIV transmission and prolonging the lifespan of people living with HIV (PLWH). Serostatus disclosure is a significant factor influencing...

Human immunodeficiency virus (HIV) vaccine trials are needed in efforts to prevent infection and acquired immunodeficiency syndrome (AIDS). Like other types of research, HIV vaccine trials present benefits and risks...